Newer v. older antidepressants in long-term pharmacotherapy. Revisiting: Prevention of relapse and recurrence of depression

Advances in Psychiatric Treatment

Volumn 11, Issue 3, 2005, Pages 184-194

  Edwards, J Guy ^a,b  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARTEMETHER PLUS BENFLUMETOL; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYCLOSPORIN; DIGOXIN; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LINEZOLID; LITHIUM; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; OXYPERTINE; PAROXETINE; PETHIDINE; PHENELZINE; PIMOZIDE; PLACEBO; PROTEINASE INHIBITOR; REBOXETINE; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SOTALOL; TELITHROMYCIN; TERFENADINE; TETRABENAZINE; THEOPHYLLINE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN; ZOLMITRIPTAN;

ANTICHOLINERGIC EFFECT; ARTICLE; AUTOMUTILATION; BREAST FEEDING; BUDGET; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONSTIPATION; DENTAL CARIES; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMUR FRACTURE; GASTROINTESTINAL DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOSALIVATION; HYPOTENSION; LETHALITY; MAJOR DEPRESSION; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL HEALTH; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; RECURRENT DISEASE; RELAPSE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SOMNOLENCE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TERATOGENICITY;

EID: 18844402645     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.11.3.184     Document Type: Article

References (54)

1. Anderson, I. (1997) Lessons to be learnt from meta-analyses of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 58-63.
2. Anderson, I. M. & Edwards, J. G. (2001) Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. Advances in Psychiatric Treatment, 7, 170-180.
3. Anderson, I. & Tomenson, B. M. (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ, 310, 1433-1438.
4. Baker, C. B., Johnsrud, M. T., Crismon, M. L., et al (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry, 183, 498-506.
5. Baldwin, D. S. (2004) Sexual dysfunction associated with antidepressant drugs. Expert Opinion in Drug Safety, 3, 457-470.
6. Barbey, J. T. & Roose, S. P. (1998) SSRI safety in overdose. Journal of Clinical Psychiatry, 59 (suppl. 15), 42-48.
7. Barbui, C., Hotopf, M., Freemantle, N., et al (2000) Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Library, issue 4. Oxford: UpdateSoftware.
8. Borys, D. J., Setzer, S. C., Ling, L. J., et al (1992) Acute fluoxetine overdose: a report of 234 cases. American Journal of Emergency Medicine, 10, 115-120.
9. British Medical Association & Royal Pharmaceutical Society of Great Britain (2004) British National Formulary 47. London & Wallingford: BMJ Books & Pharmaceutical Press.
10. Buckley, N. A. & McManus, P. R. (2002) Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ, 325, 1332-1333.
11. Cheeta, S., Schifano, F., Oyefesco, A., et al (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. British Journal of Psychiatry, 184, 41-47.
12. Denchant, K. L. & Clissold, S. P. (1991) Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs, 41, 225-253.
13. Donovan, S., McGrady, H., Pownall, R., et al (1993) The efficacy and tolerability of dothiepin and three selective serotonin reuptake inhibitors in the treatment of major depression: a review of six double-blind studies. Current Therapeutic Research, 54, 275-288.
14. Dunbar, G. C., Cohn, J. B., Fabre, L. F., et al (1991) A comparison of paroxetine, imipramine and placebo in depressed out-patients. British Journal of Psychiatry, 159, 394-398.
15. Edwards, J. G. (1995) Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs, 4, 141-159.
16. Edwards, J. G. (1997) Prevention of relapse and recurrence of depression: newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 52-57.
17. Edwards, J. G. (2004a) Unwanted effects of psychotropic drugs. 1. Effects on human physiological systems, mechanisms and methods of assessment. In Seminars in Clinical Psychopharmacology (2nd edn) (ed. D. J. King), pp. 573-600. London: Gaskell.
18. Edwards, J. G. (2004b) Unwanted effects of psychotropic drugs. 2. Drug interactions, effects during pregnancy and breast-feeding, pharmaco-vigilance and medico-legal considerations. In Seminars in Clinical Psychopharmacology (2nd edn) (ed. D. J. King), pp. 601-660. London: Gaskell.
19. Edwards, J. G. & Anderson, I. (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs, 57, 507-533.
20. Edwards, J. G., Inman, W. H. W., Wilton, L., et al (1997) Drug safety monitoring of 12692 patients treated with fluoxetine Human Psychopharmacology, 2, 127-137.
21. Geddes, J. R., Carney, S. M., Davies, C., et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653-661.
22. Glassman, A. H. (1997) Citalopram toxicity. Lancet, 350, 818.
23. Goldstein, D. J. & Sundell, K. (1999) A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Human Psychopharmacology, 4, 319-324.
24. Hendrick, V., Fukuchi, A., Altshuler, L., et al (2001) Use of sertraline, paroxetine and fluvoxamine by nursing women. British Journal of Psychiatry, 179, 163-166.
25. Henry, J.A. (1991) Overdose and safety with fluvoxamine. International Clinical Psychopharmacology, 6 (suppl. 3), 41-45.
26. Henry, J. A. (1997) Toxicity of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 41-45.
27. Henry, J. A., Alexander, C. A. & Sener, E. K. (1995) Relative mortality from overdose of antidepressants. BMJ, 310, 221-224.
28. Isacsson, G. & Bergman, U. (1996) Risks with citalopram in perspective, Lancet, 348, 1033.
29. Isacsson, G., Redfors, I., Wasserman, D., et al (1994) Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden. BMJ, 309, 1546-1549.
30. Jick, S. S., Dean, A. D. & Jick, H. (1995) Antidepressants and suicide. BMJ, 310, 215-218.
31. Kessing, L. V., Andersen, P. K., Mortensen, P. B., et al (1998) Recurrence of affective disorder. I. Case register study. British Journal of Psychiatry, 172, 23-28.
32. Kessing, L. V., Hansen, M. G. & Andersen, P. K. (2004) Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. British Journal of Psychiatry, 185, 372-377.
33. Klein-Schwartz, W. & Anderson, B. (1996) Analysis of sertraline-only overdoses. American Journal of Emergency Medicine, 14, 456-458.
34. Lee, A. S. & Murray, R. M. (1988) The long-term outcome of Maudsley depressives. British Journal of Psychiatry, 153, 741-751.
35. Liu, B., Anderson, G., Mittman, N., et al (1998) Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet, 351, 1303-1307.
36. MacGillivay, S., Arroll, B., Hatcher, S., et al (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis, BMJ, 326, 1014-1017.
37. Mackay, F. J., Dunn, N. R., Wilton, L. V., et al (1997) A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiology and Drug Safety, 6, 235-246.
38. Montgomery, S. A., & Kasper, S. (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology, 9 (suppl. 4), 33-40.
39. Nemeroff, C. B. (2003) Overview of the safety of citalopram, Psychopharmacology Bulletin, 37, 96-121.
40. Office of Population Censuses and Surveys (1975-1992) Mortality Statistics. Cause. Reviews of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales. London: HMSO.
41. Olver, J. S., Burrows, G. D. & Norman, T. R. (2001) Third-generation antidepressants. Do they offer advantages over the SSRIs? CNS Drugs, 15, 941-954.
42. Ostrom, M., Eriksson, A., Thorson, J., et al (1996) Fatal overdose with citalopram. Lancet, 348, 339-440.
43. Personne, M., Sjoberg, G. & Persson, H. (1997) Citalopram overdose - review of cases treated in Swedish hospitals. Journal of Toxicology and Clinical Toxicology, 35, 237-240.
44. Piccinelli, M. & Wikinson, G. (1994) Outcome of depression in Psychiatric settings. British Journal of Psychiatry, 164, 297-304.
45. Pirraglia, P.A., Rosen, A.B., Hermann, R.C., et al (2004) Cost-utility analysis studies of depression management: a systematic review. American Journal of Psychiatry, 161, 2155-2162.
46. Sarko, J. (2000) Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Pharmacological Advances in Emergency Medicine, 18, 637-654.
47. Shah, R., Uren, Z., Baker, A., et al (2001) Deaths from antidepressants in England and Wales 1993-1997: analysis of a new national database. Psychological Medicine, 31, 1203-1210.
48. Simon, G.E., VonKorff, M., Heiligenstein, J.H., et al (1996) Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. Journal of the American Medical Association, 275, 1897-1902.
49. Spijker, J., de Graff, R., Bijl, B. V., et al (2002) Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS), British Journal of Psychiatry, 181, 208-213.
50. Teicher, M. H., Glod, C. & Cole, J. O. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
51. Trindale, E. & Menon, D. (1997) Selective Srotonin Reuptake Inhibitors (SSRIs) for Major Depression. Part I. Evaluation of the Clinical Literature. Technology Assessment, Report 3E. Ottawa: Canadian Coordinating Office for Health.
52. Van Larr, M. W., van Willgenburg, A. P. P. & Vokerts, E. R. (1995) Acute and subchronic effects of nefazodone and imipramine on highway driving cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. Journal of Clinical Pharmacology, 15, 30-40.
53. Wilton, L. V., Pearce, G. L., Martin, R. M., et al (1998) The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. British Journal of Obstetrics and Gynaecology, 105, 882-889.
54. Yoshida, K., Smith., B. & Kumar, R. (1999) Psychotropic drugs in mother's milk: a comprehensive review of assay methods, pharmacokinetics and of safety in breastfeeding. Journal of Psychopharmacology, 131, 64-80.